New antibody shows promise in early trial for tough colorectal cancer

NCT ID NCT03017807

Completed Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new antibody drug (similar to cetuximab) in 18 people with advanced colorectal cancer that had stopped responding to standard treatments. The main goal was to check safety and how the drug moves through the body. Participants received one of two dose levels, and researchers watched for side effects like skin reactions and lung problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant Anti-EGFr Antibody (similar to cetuximab)
What this could lead to: If successful, this could lead to a new treatment option for patients with metastatic colorectal cancer who have not responded to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 18 participants, so safety and dosing are still being figured out. The drug may not work or could cause serious side effects like severe skin reactions or lung problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Locations

Sichuan Kelun Pharmaceutical Co., Ltd.

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.